Latest Period
Q1 2026
Security Snapshot
Alnylam Pharmaceuticals Inc - Common Stock Institutional Ownership
CUSIP: 02043Q107
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
23
Shares (Excl. Options)
561,669
Price
$330.87
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 561,669
- Total 13F value
- $173,230,438
- Share change
- 0
- Number of holders
- 23
- Shares outstanding
- 130,175,523
- SEC-reported price per share
- $330.87
Latest holder snapshot
2 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 02043Q107 - Alnylam Pharmaceuticals Inc - Common Stock is tracked under CUSIP 02043Q107.
- 23 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 4 to 23 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $6,723,054,234 to $173,230,438.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 23 institutions filings for Q1 2026.
Security key
02043Q107
Latest holder period
Q1 2026
13F holders
23
13D/G owners
1
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02043Q107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
02043Q107
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 10% | 13,056,605 | The Vanguard Group | 31 Mar 2025 |
As of 31 Mar 2026, 23 institutional investors reported holding 561,669 shares of Alnylam Pharmaceuticals Inc - Common Stock. This represents 0.43% of the company’s total 130,175,523 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q1 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 561,669 | $173,230,438 | $330.87 | 23 | |
| 2025 Q4 | 16,906,964 | $6,723,054,234 | +$106,439,276 | $397.65 | 4 |
| 2024 Q3 | 3,468,315 | $953,890,674 | -$18,295,271 | $275.03 | 1 |
| 2024 Q2 | 13,082,499 | $3,179,047,257 | +$210,466,917 | $243.00 | 2 |
| 2024 Q1 | 12,216,380 | $1,825,737,990 | +$86,189,757 | $149.45 | 2 |
| 2023 Q4 | 11,639,667 | $2,227,948,658 | $191.41 | 2 |